Lexeo Therapeutics (LXEO) Current Assets (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Current Assets data on file, last reported at $200.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 90.8% year-over-year to $200.9 million; the trailing twelve-month figure through Mar 2026 stood at $200.9 million (up 90.8% YoY), and the FY2025 full-year result was $188.4 million, up 49.37% from the prior year.
• Current Assets advanced to $200.9 million in Q1 2026, from $188.4 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $200.9 million in Q1 2026 to a low of $38.9 million in Q3 2023.
• A 5-year average of $138.9 million and a median of $133.9 million in 2025 frame the typical range for Current Assets.
• Across the five-year window, Current Assets soared 310.19% in 2024 and plunged 46.86% in 2025, its largest moves.
• Tracing LXEO's Current Assets over 5 years: stood at $80.0 million in 2022, then surged by 55.27% to $124.3 million in 2023, then gained by 1.47% to $126.1 million in 2024, then surged by 49.37% to $188.4 million in 2025, then climbed by 6.62% to $200.9 million in 2026.
• Business Quant data shows LXEO's Current Assets at $200.9 million in Q1 2026, $188.4 million in Q4 2025, and $127.8 million in Q3 2025.